We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

168 hedge funds and large institutions have $1.46B invested in Rocket Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 77 increasing their positions, 41 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

424% more call options, than puts

Call options by funds: $18.9M | Put options by funds: $3.6M

88% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 41

33% more capital invested

Capital invested by funds: $1.1B → $1.46B (+$362M)

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

2% more funds holding

Funds holding: 164 → 168 (+4)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

8.2% less ownership

Funds ownership: 104.58% → 96.38% (-8.2%)

Holders
168
Holders Change
+4
Holders Change %
+2.44%
% of All Funds
2.7%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
77
Reduced
41
Closed
24
Calls
$18.9M
Puts
$3.6M
Net Calls
+$15.3M
Net Calls Change
+$5.95M

Top Buyers

1
RI
RTW Investments
New York
+$34.7M
2
APM
Avidity Partners Management
Texas
+$28.1M
3
BlackRock
BlackRock
New York
+$20.1M
4
MC
Maverick Capital
Texas
+$15.9M
5
Citadel Advisors
Citadel Advisors
Florida
+$15.4M

Top Sellers

1
TCM
Tang Capital Management
California
-$20.2M
2
Goldman Sachs
Goldman Sachs
New York
-$18.6M
3
DM
Deerfield Management
New York
-$13.9M
4
Morgan Stanley
Morgan Stanley
New York
-$12.2M
5
HM
HealthCor Management
New York
-$7.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
CUAMC
151
China Universal Asset Management Company
China
$15K +$2.78K +151 +24%
N
152
Natixis
France
$13.6K +$12.8K +694 New
SO
153
STRS Ohio
Ohio
$11K +$11.1K +600 New
Balyasny Asset Management
154
Balyasny Asset Management
Illinois
$10.6K -$907K -49,228 -99%
CB
155
Centennial Bank
Arkansas
$9.79K +$9.21K +500 New
S
156
SignatureFD
Georgia
$8.16K – – –
WAM
157
Wolverine Asset Management
Illinois
$7.81K +$7.35K +399 New
TWA
158
TCI Wealth Advisors
Arizona
$6.5K – – –
Daiwa Securities Group
159
Daiwa Securities Group
Japan
$6K +$1.58K +86 +39%
HWMA
160
Heritage Wealth Management (Arizona)
Arizona
$3.91K +$1.84K +100 +100%
QCG
161
Quadrant Capital Group
Ohio
$2.04K – – –
LC
162
Lindbrook Capital
California
$1.72K – – –
FHA
163
First Horizon Advisors
Tennessee
$1.02K +$958 +52 New
IA
164
IFP Advisors
Florida
$1K +$92 +5 +25%
MFG
165
Mendota Financial Group
Wisconsin
$881 +$829 +45 New
NFSG
166
Newbridge Financial Services Group
Florida
$352 – – –
Northwestern Mutual Wealth Management
167
Northwestern Mutual Wealth Management
Wisconsin
$20 +$18 +1 New
TCM
168
Tang Capital Management
California
– -$20.2M -1,265,900 Closed
DM
169
Deerfield Management
New York
– -$13.9M -870,000 Closed
Millennium Management
170
Millennium Management
New York
– -$3.52M -220,586 Closed
Voloridge Investment Management
171
Voloridge Investment Management
Florida
– -$2.94M -184,455 Closed
CSS
172
Cubist Systematic Strategies
Connecticut
– -$2.51M -157,109 Closed
Man Group
173
Man Group
United Kingdom
– -$1.69M -106,026 Closed
PP
174
PDT Partners
New York
– -$1.44M -90,217 Closed
GCM
175
Graham Capital Management
Connecticut
– -$1.09M -68,126 Closed
4 5 6
7
8

RCKT Hedge Fund Activity: Q4 2022 in Review

168 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2022, worth a combined $1.46B — up 33% from $1.1B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new RCKT positions and 24 closed out — a net gain of 7 holders — while 77 added to existing stakes and 41 trimmed.

The largest buyer was RTW Investments, adding an estimated $34.7M. The largest seller was Tang Capital Management, exiting entirely with an estimated $20.2M sold.

  • 168 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2022, up from 164 in Q3 2022.
  • Funds reported $1.46B of Rocket Pharmaceuticals stock for Q4 2022, up 33% quarter-over-quarter.
  • 31 funds opened new Rocket Pharmaceuticals positions in Q4 2022 and 24 closed out, a net change of +7 holders.
  • The largest Rocket Pharmaceuticals buyer in Q4 2022 was RTW Investments, an estimated $34.7M added.
  • The largest Rocket Pharmaceuticals seller in Q4 2022 was Tang Capital Management, an estimated $20.2M sold.

Based on aggregated 13F filings for Q4 2022.